CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AngioGenex, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AngioGenex, Inc.
425 Madison Ave Ste 902
Phone: (212) 874-6608p:212 874-6608 New York City, NY  10017-1110  United States Fax: (212) 874-5027f:212 874-5027
This company is no longer actively traded on any major stock exchange.
Business Summary
AngioGenex, Inc. is a biopharmaceutical company, which is engaged in discovering and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. The Company and its collaborators, including Robert Benezra, Ph.D. and The Robert Benezra Lab at Sloan Kettering Institute, have assembled key platform enabling technologies and tools that allow for the identification of specific and potent small molecule binders of Id. Its Anti-Id platform gave rise to AGX-A, an investigational small molecule designed to selectively bind to Id proteins, thereby targeting them for degradation and reducing resulting tumor growth and neovascularization. The Company’s lead development candidate is AGX-A, a small molecule being investigated for the treatment of cholangiocarcinoma and age-related macular degeneration (AMD).
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201912/31/2018YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Michael C.Aronstein 66 9/12/2019 11/28/2017
Chief Financial Officer, Director Martin F.Murray 52 1/1/2005 1/1/1999
Vice President, Chief Operations Officer, Business Development, Director Michael M.Strage 59 11/1/2017 1/1/1999
Independent Director RobertDickey 66 6/30/2020 6/30/2020

Business Names
Business Name
AGGX
AngioGenex Inc.
AngioGenex, Inc.
ECLIC INC/NV

General Information
Outstanding Shares: 30,386,667 (As of 8/14/2019)
Shareholders: 217
Stock Exchange: OTC
Federal Tax Id: 860945116
Fax Number: (212) 874-5027
Email Address: info@angiogenex.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023